Non Small Cell Lung Cancer Clinical Trials in Orange, California

16 studies are recruiting for non small cell lung cancer in Orange, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Orange, California
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  2. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange, California
    Locations
    269 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312137 on ClinicalTrials.gov

  3. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California Irvine, Orange, California
    Locations
    202 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT07195695 on ClinicalTrials.gov

  4. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California
    Locations
    38 in total
    Run by
    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

  5. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California Irvine, Orange, California
    Locations
    280 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

  6. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Providence St. Joseph Hospital, Orange, California
    Locations
    118 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07185997 on ClinicalTrials.gov

  7. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Orange, California
    Locations
    167 in total
    Run by
    AstraZeneca

    See if you can join NCT06350097 on ClinicalTrials.gov

  8. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (N…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California, Irvine Health, Orange, California
    Locations
    158 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT06765109 on ClinicalTrials.gov

  9. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California
    Locations
    186 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

  10. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

    The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074), Orange, California
    Locations
    229 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06077760 on ClinicalTrials.gov

  11. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

    This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
    Run by
    University of California, Irvine

    See if you can join NCT07064018 on ClinicalTrials.gov

  12. A Study of VET3-TGI in Patients With Solid Tumors

    VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UC Irvine Health, Orange, California
    Locations
    7 in total
    Run by
    KaliVir Immunotherapeutics

    See if you can join NCT06444815 on ClinicalTrials.gov

  13. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center, Orange, California
    Locations
    26 in total
    Run by
    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

  14. Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

    This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
    Run by
    University of California, Irvine

    See if you can join NCT06221800 on ClinicalTrials.gov

  15. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California Irvine Medical Center, Orange, California
    Locations
    39 in total
    Run by
    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

  16. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Orange, California
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.